Cost-effectiveness of stroke treatments and secondary preventions

Bibliography

• Demaerschalk B, Hwang H, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care 2010;16(7):525-33
   PubMedGoogle Scholar
• Mackay J, Mensah GA. World health organization. the atlas of heart disease and stroke. 2004. Available from: http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf [Last accessed 11 August 2011]
   Google Scholar
• Heart and Stroke Foundation. Stroke statistics. 2011. Available from: http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm [Last accessed 8 August 2011]
   Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, Heart disease and stroke statistics–2011 update: a report from the American heart association. Circulation 2011;123:e18-e209
   PubMed Web of Science ®Google Scholar
• Furie K, Kasner S, Adams R, Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:227-76
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Stroke: national clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). Royal College of Physicians; London: 2008
   Google Scholar
• Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health 2009;12:507-20
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011;377(9778):1681-92
   PubMed Web of Science ®Google Scholar
• Sinclair SE, Frighetto L, Loewen PS, Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-36
   PubMed Web of Science ®Google Scholar
• Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002;5:82-97
   PubMed Web of Science ®Google Scholar
• Moodie ML, Carter R, Mihalopoulos C, Trial application of a model of resource utilization, costs, and outcomes for stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004;35:1041-6
   PubMed Web of Science ®Google Scholar
• Sandercock P, Berge E, Dennis M, Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7
   PubMed Web of Science ®Google Scholar
• Mihalopoulos C, Cadilhac DA, Moodie ML, Development and application of model of resource utilization, costs, and outcomes for stroke (MORUCOS): an Australian economic model for stroke. Int J Technol Assess Health Care 2005;21:499-505
   PubMedGoogle Scholar
• Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005;20:193-200
   PubMedGoogle Scholar
• Ehlers L, Andersen G, Clausen LB, Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007;38:85-9
   PubMed Web of Science ®Google Scholar
• Johnston SC. The economic case for new stroke thrombolytics. Stroke 2010;41:S59-62
   Google Scholar
• Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006;37:2751-8
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36(11):2500-3
   PubMedGoogle Scholar
• Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke 2007;38(6):1952-5
   PubMedGoogle Scholar
• Burn J. The outcome of a first stroke: the Oxford community stroke project [MD thesis]. 1991. Available from: www.nip.dk [Last accessed 19 July 2011]
   Google Scholar
• Solomon NA, Glick HA, Russo CJ, Patient preferences for stroke outcomes. Stroke 1994;25:1721-5
   PubMed Web of Science ®Google Scholar
• Fagan SC, Morgenstern LB, Petitta A, Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-90
   PubMed Web of Science ®Google Scholar
• Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-91
   PubMed Web of Science ®Google Scholar
• Ringleb PA, Schwark C, Schwaninger M, Schellinger PD. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. Expert Opin Pharmacother 2005;6:359-67
   PubMed Web of Science ®Google Scholar
• Kirshner H. Secondary stroke prevention and management: an evidence-based update for managed care: an examination of guideline-recommended treatment strategies for optimal individualized care and improvement of outcomes in the prevention of secondary stroke. 2008. Available from: http://www.cecentral.com/assets/1419/xen09028_content_FINAL.pdf [Last accessed 28 January 2012]
   Google Scholar
• Heeg B, Damen J, Van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Pharmacoeconomics 2007;25:1063-82
   PubMedGoogle Scholar
• Beard SM, Gaffney L, Bamber L, De Platchett J. Economic modelling of antiplatelet therapy in the secondary prevention of stroke. J Med Econ 2004;7:117-34
   Google Scholar
• Jones L, Griffin S, Palmer S, Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii-v; 1-196
   Google Scholar
• Karnon J, Brennan A, Pandor A, Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin 2005;21:101-12
   PubMed Web of Science ®Google Scholar
• Marissal JP, Selke B. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. Pharmacoeconomics 2004;22:661-70
   PubMed Web of Science ®Google Scholar
• Matchar DB, Samsa GP, Liu S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. Value Health 2005;8:572-80
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773-8
   PubMedGoogle Scholar
• Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004;116:797-806
   PubMed Web of Science ®Google Scholar
• Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin Ther 2000;22:362-70
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Ward A, Roberts CS, Economic valuation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health 2009;12(6):880-7
   PubMedGoogle Scholar
• Desbiens NA. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J Am Geriatr Soc 2002;50:863-9
   PubMedGoogle Scholar
• Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998;114:699S-714S
   Google Scholar
• Freeman JV, Zhu RP, Owens DK, Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan III A, Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. high-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):549-59
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener HC, Yusuf S, PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359(12):1238-51
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Dewilde S, Singer DE, Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73
   PubMedGoogle Scholar
• Available from: http://guidance.nice.org.uk/TA210 [Last accessed 11 November 2011]
   Google Scholar
• O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar